GenSight Biologics Reports €3.2M Cash Position, €2.6M Early Access Revenue

Event summary

  • GenSight Biologics reported €3.2M in cash and cash equivalents as of March 31, 2026, up from €2.4M at the end of 2025.
  • The company recorded €2.6M in revenue from its Named Patient Early Access Program in March 2026.
  • GenSight raised €1.7M in March 2026 to buffer delays in French hospital system payments.
  • The price of GS010/LUMEVOQ® treatment under the French Early Access Program is set at €425,000 per injection.
  • The company expects to initiate a Paid Named Patient Program in Israel in Q2 2026.

The big picture

GenSight Biologics is leveraging early access programs to sustain operations while advancing its gene therapy pipeline. The company's ability to manage cash flow and regulatory timelines will be critical as it navigates the transition from clinical development to potential commercialization. The strategic focus on rare retinal diseases positions GenSight within a niche but growing segment of the biopharma industry.

What we're watching

Revenue Sustainability
Whether aggregate revenues from early access programs will cover operating expenses excluding Phase III RECOVER trial costs.
Regulatory Timing
The pace at which the Phase III RECOVER study progresses and its impact on cash burn.
Geographic Expansion
How the initiation of the Paid Named Patient Program in Israel affects revenue diversification.

Related topics

Revenue